Background Pre-clinical data demonstrates the ability of Exenatide, a GLP-1R agonist, to reduce CSF secretion and ICP.1 Existing GLP-1R agonists are widely used to treat obesity and diabetes (but do ...

OBJECTIVES To clarify the nosological relation among Miller Fisher syndrome (MFS), Guillain-Barré syndrome (GBS) with ophthalmoplegia, Bickerstaff's brain stem encephalitis (BBE), and acute ...

Symptoms in cognitive disorders follow location and not pathology. Thus, for example, in Alzheimer’s disease, patients may present with a focal language syndrome, instead of the more commonly ...

Background: Hereditary spastic paraplegias (HSP) are clinically and genetically highly heterogeneous. Recently, two novel genes, SPG11 ( spatacsin ) and SPG15 ( spastizin ), associated with autosomal ...

Background We aimed to describe neuroimaging features, clinical profiles and long-term outcomes in patients with iatrogenic cerebral amyloid angiopathy (iCAA). Methods We performed a systematic ...

In 1907, George Hoyt Whipple, then an instructor in pathology at Johns Hopkins University, published a case report of a 36 year old physician who had been domiciled in Constantinople.1 He developed ...

Background: Gluten ataxia is an immune mediated disease, part of the spectrum of gluten sensitivity, and accounts for up to 40% of cases of idiopathic sporadic ataxia. No systematic study of the ...

OBJECTIVES To investigate the prevalence of orthostatic hypotension and the nature of the postural events related to a fall in blood pressure in patients with Parkinson’s disease. METHODS Blood ...

Background: Complaints of persistent cognitive deficits following mild head trauma are often uncorroborated by structural brain imaging and neuropsychological examination. Objective: To investigate, ...

Background Status epilepticus is a medical emergency and carries a high mortality. Early seizure control is important to prevent neurological complications. In our centre, phenytoin loading is given ...

Background Current international guidelines suggest andexanet alfa (AA) for the management of factor Xa inhibitor-associated intracranial haemorrhage (ICH). However, those recommendations are based on ...

Objectives To investigate, in patients with Alzheimer's Disease (AD), the possible interplay linking alteration of neuronal energy metabolism, as measured via cerebrospinal fluid (CSF) lactate ...